Dr. Robert Booth brings over 30 years of experience in the biopharmaceutical industry to Thryv Therapeutics. He is the founder and former Chief Executive Officer of Virobay Inc., where he led the company's strategic direction and growth. He has also served as an Operating Partner and Senior Advisor at TPG Biotech, providing strategic guidance to life sciences companies.

Previously, Dr. Booth was the Chief Scientific Officer at Celera Genomics, where he oversaw all discovery and development activities. He conceived and initiated the BTK inhibitor program, which was licensed to Pharmacyclics and led to the development and approval of Imbruvica®, a novel kinase inhibitor used to treat various B-cell non-Hodgkin's lymphomas (NHL). Dr. Booth served on the board of directors of Pharmacyclics until its acquisition by AbbVie.

Earlier in his career, Dr. Booth was Senior Vice President at Roche in Palo Alto, California. He was a member of Roche's Global Research Management Team and the Business Development Committee, where he evaluated and managed licensing opportunities.

Dr. Booth holds a PhD in Biochemistry and a BSc, both from the University of London.